← Leaderboards
Steven R Duncan
Scripps Research Institute
$7,851,240
Attributed
$12,612,455
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2006–21$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$12,612,455 · 7
By mechanism
R01$5,934,711 · 3
U01$4,226,921 · 2
P01$1,592,176 · 1
P50$858,647 · 1
Top collaborators
- Daniel J Kass10 shared
- Gerard J Criner5 shared
- Ivan O. Rosas5 shared
- Kevin Fitzgerald Gibson4 shared
Most similar at Scripps Research Institute
Same institution · by research overlap
- Gary M Bokoch$16,209,920
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungInvestigationMediatingLeadClinical TrialsLung DiseasesPathogenesisRefractoryElderlyMedicalPlasmaPlayInvestigational TherapiesPharmaceutical PreparationsTreatment EffectModalityAdverse EventProductionMedical CenterFutureRandomizedB-LymphocytesGlucocorticoidsBiological Markers
Grant awards (28)
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$700,683
U01 · FY2021 · HL · contact PI
Phase II Clinical Trial of the Safety and Efficacy if a NOX1/4 Inhibitor in IPF$521,169
P01 · FY2021 · HL · contact PI
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$753,012
U01 · FY2020 · HL · contact PI
Phase II Clinical Trial of the Safety and Efficacy if a NOX1/4 Inhibitor in IPF$142,856
P01 · FY2020 · HL · contact PI
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$771,021
U01 · FY2019 · HL · contact PI
Phase II Clinical Trial of the Safety and Efficacy if a NOX1/4 Inhibitor in IPF$569,669
P01 · FY2019 · HL · contact PI
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$771,021
U01 · FY2018 · HL · contact PI
Rituximab Therapy in Patients with IPF$673,150
R01 · FY2018 · HL · contact PI
Phase II Clinical Trial of the Safety and Efficacy if a NOX1/4 Inhibitor in IPF$358,482
P01 · FY2018 · HL · contact PI
Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis$787,346
U01 · FY2017 · HL · contact PI
Rituximab Therapy in Patients with IPF$682,198
R01 · FY2017 · HL · contact PI
Rituximab Therapy in Patients with IPF$673,599
R01 · FY2016 · HL · contact PI
Rituximab Therapy in Patients with IPF$643,011
R01 · FY2014 · HL · contact PI
Impact of CCR5 inhibition on Sarcoid Immunophenotypes$148,350
U01 · FY2014 · HL
Rituximab Therapy in Patients with IPF$58,456
R01 · FY2014 · HL · contact PI
Rituximab Therapy in Patients with IPF$673,554
R01 · FY2013 · HL · contact PI
Impact of CCR5 inhibition on Sarcoid Immunophenotypes$144,111
U01 · FY2013 · HL
The Role of Humoral Autoimmunity in Idiopathic Pulmonary Fibrosis$408,480
P50 · FY2012 · HL · contact PI
Impact of CCR5 inhibition on Sarcoid Immunophenotypes$151,377
U01 · FY2012 · HL
The Role of Humoral Autoimmunity in Idiopathic Pulmonary Fibrosis$450,167
P50 · FY2011 · HL · contact PI
Clonal CD4 T-Cells in Lung Transplant Recipients$355,774
R01 · FY2009 · HL · contact PI
Clonal CD4 T-Cells in Lung Transplant Recipients$355,774
R01 · FY2008 · HL · contact PI
Clonal CD4 T-Cells in Lung Transplant Recipients$355,774
R01 · FY2007 · HL · contact PI
Clonal CD4 T-Cells in Lung Transplant Recipients$366,400
R01 · FY2006 · HL · contact PI
DENDRITIC CELLS FOR INDUCTION OF ALLOGRAFT TOLERANCE$272,998
R01 · FY2003 · HL
DENDRITIC CELLS FOR INDUCTION OF ALLOGRAFT TOLERANCE$265,924
R01 · FY2002 · HL
DENDRITIC CELLS FOR INDUCTION OF ALLOGRAFT TOLERANCE$259,035
R01 · FY2001 · HL
DENDRITIC CELLS FOR INDUCTION OF ALLOGRAFT TOLERANCE$299,064
R01 · FY2000 · HL